GHRP-6

Discovery and Structure

GHRP-6 is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂. It was developed in the 1980s by Cyril Y. Bowers at Tulane University during a long-running effort to engineer small peptides capable of releasing growth hormone by a mechanism distinct from GHRH. GHRP-6 was the compound that crystallized that hypothesis — its GH-releasing activity could not be explained by GHRH signaling, which led directly to the 1996 discovery of the GH secretagogue receptor (GHS-R1a) and, in 1999, to the identification of its endogenous ligand, ghrelin.

Historically, GHRP-6 is important less for its own clinical profile than for what it taught endocrinology: it was the tool compound that forced researchers to accept the existence of a second, ghrelin-dependent axis regulating pituitary GH release.

Mechanism of Action

GHRP-6 is an agonist at the ghrelin receptor (GHSR-1a) expressed on anterior pituitary somatotrophs and in several hypothalamic nuclei including the arcuate. Receptor activation produces pulsatile GH release that synergizes with simultaneous GHRH signaling — the two pathways converge on somatotroph GH secretion through distinct intracellular cascades.

What makes GHRP-6 pharmacologically distinctive among GHRPs is the strength of its non-GH effects. It is a potent orexigenic — activation of arcuate GHSR-1a drives marked appetite stimulation via NPY/AgRP neurons, often dose-dependently. It also produces clinically meaningful increases in cortisol and prolactin, reflecting promiscuous pituitary activation beyond the somatotroph.

Clinical Evidence

GHRP-6 has been extensively studied as a research probe but has no FDA-approved indication. Relevant human work includes:

• GH stimulation testing. GHRP-6, alone or combined with GHRH, has been validated as a diagnostic agent for adult GH deficiency in academic trials, though it was never commercialized for that purpose — a niche that macimorelin ultimately occupied.
• Cachexia and appetite stimulation. Early-phase trials explored GHRP-6 for cancer- and HIV-related wasting, exploiting the appetite-stimulating effect rather than the GH axis itself.
• Cytoprotection. A Cuban research program led by the Center for Genetic Engineering and Biotechnology has pursued GHRP-6 as a cytoprotective agent in myocardial infarction and burn injury, reporting benefits in small trials that have not been widely replicated internationally.

No Phase 3 program has advanced GHRP-6 to approval. The compound is best understood as a historically important research tool with a thin clinical evidence base.

Practical Considerations

Research protocols typically use 100-300 mcg subcutaneously, two to three times daily, dosed fasted to avoid the blunting effect of circulating glucose and amino acids on ghrelin-receptor signaling. The marked appetite effect is the single most important practical difference from newer GHRPs — users report strong hunger within 30-60 minutes of injection, which is valued in muscle-building contexts and avoided in fat-loss ones. For appetite-neutral alternatives within the same mechanistic class, see ipamorelin, and for a broader comparison of GH-releasing strategies see our recovery peptide guide.

Safety and Regulatory Status

The most consistently reported effects are appetite increase, water retention, transient flushing, and mild headache. Cortisol and prolactin elevations are real but modest at standard doses, and they are what pushed the field toward more selective compounds. Receptor desensitization with continuous dosing is a known concern across the GHRP class, and cycling protocols (typically 8-12 weeks on, followed by a washout) are common in research-use settings.

GHRP-6 is not FDA-approved. It sits on the WADA prohibited list at all times (class S2). Supply is almost entirely through research-chemical vendors and compounding pharmacies, with the usual caveats about purity and regulatory status.